Scleroderma Clinical Trial
— GYYBOfficial title:
Assessing a Gentle Yoga Combined With Yoga Breathing (GYYB) Adjunct Intervention for Scleroderma Self-Management
Verified date | January 2024 |
Source | Medical University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot research study to determine the feasibility of gentle yoga and breathing exercises for symptom management in patients with scleroderma. Participants will have a first study visit that includes completing demographic and quality-of-life surveys, learning the gentle yoga and breathing exercises, and providing two saliva samples before and after doing the exercises. After this visit, participants will do the gentle yoga and breathing exercises twice daily at home (morning and evening) by following a video hyperlink. Participants will make an entry in their Yoga Practice Diaries each time they practice at home. On the 12th Week, participants will return to MUSC for a final study visit that includes doing the gentle yoga and breathing exercises, providing saliva samples, and completing a satisfaction survey. There will be a total of 2 clinic visits (on Weeks 1 and 12). The study coordinator will telephone participants weekly during the 10 weeks that they do the gentle yoga and breathing exercises at home to answer questions and help solve any problems. Each visit will take about 2 hours for this research study, in addition to any routine clinical examinations. Each home yoga and breathing practice will take 1 hour. The total study duration is 12 Weeks (3 months). Participants will receive compensation for their travel in the form of prepaid Visa gift cards.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | July 30, 2024 |
Est. primary completion date | July 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men and women fulfilling the 2013 ACR/EULAR Classification for Systemic Sclerosis - Self-identified race/ethnicity as AA or NHW - Undergoing treatment from any healthcare provider - 18 years of age or older - Ability to perform the study exercises involving gentle movements sitting on a chair and regulated breathing - Access to a working telephone - Access to watch a video from a DVD or from a website or Youtube Exclusion Criteria: - Diagnosed with psychiatric or cognitive disorder that precludes provision of written informed consent - Physical limitations making Yoga techniques detrimental - Enrolled in any other Yoga related clinical trials - Currently engaged in regular Yoga activity (once per week or more). |
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | Marvella Ford, Paul Nietert, Richard Silver, Therese Killeen |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of life determination: SHAQ-DI | Scleroderma Health Assessment Questionnaire and Disability Index (SHAQ-DI) | 12 weeks | |
Primary | Perceived Stress | Perceived Stress Scale | 12 weeks | |
Primary | Depression | 10-item Center for Epidemiologic Studies Depression Scale | 12 weeks | |
Primary | Salivary biomarkers | IL-1ß, IL-8 , IL-6, and MCP-1, and cortisol | Weeks 0 and 12 | |
Primary | Feasibility test | enrollment data | Week 12 | |
Primary | Adherence | Practice diary | 12 weeks | |
Primary | Acceptance | Satisfaction using likert scale | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02798055 -
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
|
||
Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
Completed |
NCT02915835 -
Riociguat in Scleroderma Associated Digital Ulcers
|
Phase 2 | |
Active, not recruiting |
NCT01895244 -
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT00930683 -
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
|
Phase 1 | |
Completed |
NCT00883129 -
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
|
Phase 2 | |
Completed |
NCT00074568 -
Scleroderma Registry
|
||
Recruiting |
NCT04797286 -
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
|
Phase 2 | |
Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT03207997 -
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
|
N/A | |
Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A | |
Completed |
NCT05080738 -
Upper Extremity Home Exercises in Patients With Scleroderma
|
N/A | |
Recruiting |
NCT03726398 -
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
|
Phase 2/Phase 3 | |
Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
Completed |
NCT02062125 -
Calcinosis in a Single-Center Scleroderma Population
|
||
Completed |
NCT04588714 -
Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT02835196 -
Optical Elastography of Systemic Sclerosis Skin
|